A multivalent approach to drug discovery for novel antibiotics. 2008

Daniel D Long, and James B Aggen, and Burton G Christensen, and J Kevin Judice, and Sharath S Hegde, and Koné Kaniga, and Kevin M Krause, and Martin S Linsell, and Edmund J Moran, and John L Pace
Theravance, Inc., San Francisco, CA 94080, USA. dlong@theravance.com

The design, synthesis and antibacterial activity of novel glycopeptide/beta-lactam heterodimers is reported. Employing a multivalent approach to drug discovery, vancomycin and cephalosporin synthons, A and B respectively, were chemically linked to yield heterodimer antibiotics. These novel compounds were designed to inhibit Gram-positive bacterial cell wall biosynthesis by simultaneously targeting the principal cellular targets of both glycopeptides and beta-lactams. The antibiotics 8a-f displayed remarkable potency against a wide range of Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA). Compound 8e demonstrated excellent bactericidal activity against MRSA (ATCC 33591) and initial evidence supports a multivalent mechanism of action for this important new class of antibiotic.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002473 Cell Wall The outermost layer of a cell in most PLANTS; BACTERIA; FUNGI; and ALGAE. The cell wall is usually a rigid structure that lies external to the CELL MEMBRANE, and provides a protective barrier against physical or chemical agents. Cell Walls,Wall, Cell,Walls, Cell
D006020 Glycopeptides Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight. Glycopeptide
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D047090 beta-Lactams Four-membered cyclic AMIDES, best known for the PENICILLINS based on a bicyclo-thiazolidine, as well as the CEPHALOSPORINS based on a bicyclo-thiazine, and including monocyclic MONOBACTAMS. The BETA-LACTAMASES hydrolyze the beta lactam ring, accounting for BETA-LACTAM RESISTANCE of infective bacteria. beta-Lactam,4-Thia-1-Azabicyclo(3.2.0)Heptanes,4-Thia-1-Azabicyclo(4.2.0)Octanes,beta Lactam,beta Lactams
D055624 Methicillin-Resistant Staphylococcus aureus A strain of Staphylococcus aureus that is non-susceptible to the action of METHICILLIN. The mechanism of resistance usually involves modification of normal or the presence of acquired PENICILLIN BINDING PROTEINS. MRSA,Methicillin Resistant Staphylococcus aureus
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug

Related Publications

Daniel D Long, and James B Aggen, and Burton G Christensen, and J Kevin Judice, and Sharath S Hegde, and Koné Kaniga, and Kevin M Krause, and Martin S Linsell, and Edmund J Moran, and John L Pace
November 2014, Medicinal research reviews,
Daniel D Long, and James B Aggen, and Burton G Christensen, and J Kevin Judice, and Sharath S Hegde, and Koné Kaniga, and Kevin M Krause, and Martin S Linsell, and Edmund J Moran, and John L Pace
June 2001, Drug discovery today,
Daniel D Long, and James B Aggen, and Burton G Christensen, and J Kevin Judice, and Sharath S Hegde, and Koné Kaniga, and Kevin M Krause, and Martin S Linsell, and Edmund J Moran, and John L Pace
December 2002, Current drug targets. Infectious disorders,
Daniel D Long, and James B Aggen, and Burton G Christensen, and J Kevin Judice, and Sharath S Hegde, and Koné Kaniga, and Kevin M Krause, and Martin S Linsell, and Edmund J Moran, and John L Pace
August 2019, Trends in pharmacological sciences,
Daniel D Long, and James B Aggen, and Burton G Christensen, and J Kevin Judice, and Sharath S Hegde, and Koné Kaniga, and Kevin M Krause, and Martin S Linsell, and Edmund J Moran, and John L Pace
April 2018, Expert opinion on drug discovery,
Daniel D Long, and James B Aggen, and Burton G Christensen, and J Kevin Judice, and Sharath S Hegde, and Koné Kaniga, and Kevin M Krause, and Martin S Linsell, and Edmund J Moran, and John L Pace
November 2022, Nature reviews. Drug discovery,
Daniel D Long, and James B Aggen, and Burton G Christensen, and J Kevin Judice, and Sharath S Hegde, and Koné Kaniga, and Kevin M Krause, and Martin S Linsell, and Edmund J Moran, and John L Pace
February 2012, Expert opinion on drug discovery,
Daniel D Long, and James B Aggen, and Burton G Christensen, and J Kevin Judice, and Sharath S Hegde, and Koné Kaniga, and Kevin M Krause, and Martin S Linsell, and Edmund J Moran, and John L Pace
February 2013, Current medicinal chemistry,
Daniel D Long, and James B Aggen, and Burton G Christensen, and J Kevin Judice, and Sharath S Hegde, and Koné Kaniga, and Kevin M Krause, and Martin S Linsell, and Edmund J Moran, and John L Pace
April 2009, Journal of chemical information and modeling,
Daniel D Long, and James B Aggen, and Burton G Christensen, and J Kevin Judice, and Sharath S Hegde, and Koné Kaniga, and Kevin M Krause, and Martin S Linsell, and Edmund J Moran, and John L Pace
September 2013, Yao xue xue bao = Acta pharmaceutica Sinica,
Copied contents to your clipboard!